Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases

Journal of the Neurological Sciences

Volumn 328, Issue 1-2, 2013, Pages 77-82

  Gredler, Viktoria ^a   Mader, Simone ^a   Schanda, Kathrin ^a   Hegen, Harald ^a   Di Pauli, Franziska ^a   Kuenz, Bettina ^a   Deisenhammer, Florian ^a   Berger, Thomas ^a   Reindl, Markus ^a   Lutterotti, Andreas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Aquaporin 4; B cells; BAFF; LETM; NMO; Rituximab

Indexed keywords

AQUAPORIN 4; BETA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PREDNISOLONE; RITUXIMAB;

ADULT; ANTIBODY TITER; ARTICLE; B CELL DEPLETING THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROGENIC BLADDER; OBSERVATIONAL STUDY; OPTIC NEURITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUADRIPLEGIA; RELAPSE; SCLEROSIS; SINGLE DRUG DOSE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; AQUAPORIN 4; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LONGITUDINAL STUDIES; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; OBSERVATION; TIME FACTORS; YOUNG ADULT;

EID: 84876140113     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.02.024     Document Type: Article

References (30)

1. D.M. Wingerchuk, W.F. Hogancamp, P.C. O'Brien, and B.G. Weinshenker The clinical course of neuromyelitis optica (Devic's syndrome) Neurology 53 1999 1107 1114 (Pubitemid 29442132)
2. S.J. Pittock, V.A. Lennon, J. de Seze, P. Vermersch, H.A. Homburger, and D.M. Wingerchuk Neuromyelitis optica and non organ-specific autoimmunity Arch Neurol 65 2008 78 83
3. D.M. Wingerchuk, V.A. Lennon, S.J. Pittock, C.F. Lucchinetti, and B.G. Weinshenker Revised diagnostic criteria for neuromyelitis optica Neurology 66 2006 1485 1489 (Pubitemid 43958540)
4. V.A. Lennon, D.M. Wingerchuk, T.J. Kryzer, S.J. Pittock, C.F. Lucchinetti, and K. Fujihara A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis Lancet 364 2004 2106 2112 (Pubitemid 39626806)
5. V.A. Lennon, T.J. Kryzer, S.J. Pittock, A.S. Verkman, and S.R. Hinson IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel J Exp Med 202 2005 473 477 (Pubitemid 41186945)
6. S. Jarius, K. Ruprecht, B. Wildemann, T. Kuempfel, M. Ringelstein, and C. Geis Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients J Neuroinflammation 9 2012 14
7. S. Mader, V. Gredler, K. Schanda, K. Rostasy, I. Dujmovic, and K. Pfaller Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders J Neuroinflammation 8 2011 184
8. J. Kitley, M. Woodhall, P. Waters, M.I. Leite, E. Devenney, and J. Craig Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype Neurology 79 12 2012 1273 1277
9. Rostasy K, Mader S, Hennes E, Schanda K, Gredler V, Guenther A, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler in press [Electronic publication ahead of print].
10. J. Sellner, M. Boggild, M. Clanet, R.Q. Hintzen, Z. Illes, and X. Montalban EFNS guidelines on diagnosis and management of neuromyelitis optica Eur J Neurol 17 2010 1019 1032
11. B.A. Cree, S. Lamb, K. Morgan, A. Chen, E. Waubant, and C. Genain An open label study of the effects of rituximab in neuromyelitis optica Neurology 64 2005 1270 1272
12. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452 (Pubitemid 14237132)
13. S.L. Hauser, E. Waubant, D.L. Arnold, T. Vollmer, J. Antel, and R.J. Fox B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 2008 676 688 (Pubitemid 351240747)
14. S. Mader, A. Lutterotti, F. Di Pauli, B. Kuenz, K. Schanda, and F. Aboul-Enein Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica PLoS One 5 2010 e10455
15. K. Rostasy, S. Mader, K. Schanda, P. Huppke, J. Gärtner, and V. Kraus Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis Arch Neurol 69 6 2012 752 756
16. G.S. Bedi, A.D. Brown, S.R. Delgado, N. Usmani, B.L. Lam, and W.A. Sheremata Impact of rituximab on relapse rate and disability in neuromyelitis optica Mult Scler 17 2011 1225 1230
17. A. Jacob, B.G. Weinshenker, I. Violich, N. McLinskey, L. Krupp, and R.J. Fox Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients Arch Neurol 65 2008 1443 1448
18. S.H. Kim, W. Kim, X.F. Li, I.J. Jung, and H.J. Kim Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years Arch Neurol 68 2011 1412 1420
19. S. Jarius, F. Aboul-Enein, P. Waters, B. Kuenz, A. Hauser, and T. Berger Antibody to aquaporin-4 in the long-term course of neuromyelitis optica Brain 131 2008 3072 3080
20. J.W. Lindsey, K.M. Meulmester, S.A. Brod, F. Nelson, and J.S. Wolinsky Variable results after rituximab in neuromyelitis optica J Neurol Sci 317 1-2 2012 103 105
21. M. Capobianco, S. Malucchi, A. di Sapio, F. Gilli, A. Sala, and R. Bottero Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease) Neurol Sci 28 2007 209 211 (Pubitemid 47263843)
22. H.L. Pellkofer, M. Krumbholz, A. Berthele, B. Hemmer, L.A. Gerdes, and J. Havla Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab Neurology 76 2011 1310 1315
23. I. Nakashima, T. Takahashi, B.A. Cree, H.J. Kim, C. Suzuki, and C.P. Genain Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels J Clin Neurosci 18 2011 997 998
24. J.L. Bennett, C. Lam, S.R. Kalluri, P. Saikali, K. Bautista, and C. Dupree Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica Ann Neurol 66 2009 617 629
25. M. Bradl, T. Misu, T. Takahashi, M. Watanabe, S. Mader, and M. Reindl Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo Ann Neurol 66 2009 630 643
26. S. Saadoun, P. Waters, B.A. Bell, A. Vincent, A.S. Verkman, and M.C. Papadopoulos Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice Brain 133 2010 349 361
27. F. Lavie, C. Miceli-Richard, M. Ittah, J. Sellam, J.E. Gottenberg, and X. Mariette Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production Ann Rheum Dis 66 2007 700 703 (Pubitemid 46707145)
28. A. Nagel, E. Podstawa, M. Eickmann, H.H. Muller, M. Hertl, and R. Eming Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris J Invest Dermatol 129 2009 2202 2210
29. M. Kreuzaler, M. Rauch, U. Salzer, J. Birmelin, M. Rizzi, and B. Grimbacher Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors J Immunol 188 2012 497 503
30. N. Chihara, T. Aranami, W. Sato, Y. Miyazaki, S. Miyake, and T. Okamoto Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica Proc Natl Acad Sci U S A 108 2011 3701 3706